Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
Publishing timestamp: 2023-07-07 08:14:50
Summary
Tokyo-listed shares of Eisai fell by more than 8% after the FDA approved its Alzheimer's drug, Leqembi. There is debate among experts about the effectiveness of the drug, with some expressing concerns about its benefits and potential side effects. Factors such as the approval of a subcutaneous injector formulation and the commercialization of a blood biomarker are seen as potential drivers for the drug's success in the long term.
Sentiment: MIXED
Keywords: biotech and pharmaceuticals, world markets, business news, united states, social issues, tokyo, eisai co ltd, science, biogen inc, pharmaceuticals,
Source: https://www.cnbc.com/2023/07/07/eisai-shares-tumble-despite-receiving-fda-greenlight.html